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Most functionsattributed toTityus serrulatusvenom(TsV)are related toactivemoleculeson ion-channels;
however, here we describe a new pentapeptide that was discovered through enzymatic assay selection
using EP24.15. The primary structure analysis revealed the sequence KEXXG (X means Ile or Leu), similar
to the sequence present in the -KTX propeptide described from the venom of Tityus spp. We conﬁrmed
through HPLC analysis that KEILG is the peptide present in TsV, but that KELLG also inhibits EP24.15
although through different mechanisms.. Introduction
Since 2007, scorpionism is the major cause of human enveno-
ation by animals in Brazil, surpassing accidents with snakes and
piders [4]. Most of the critical clinical cases are attributed to Tityus
errulatus scorpions, result of its wide proliferation in the urban
enters and in the potential of its venom to induce severe clin-
cal manifestations, being even fatal among children and elders.
. serrulatus venom (TsV) contains neurotoxins capable of interac-
ing with the nervous system via ion channels and, because of that,
esearch studies focus on neurotoxins descriptions and theirmech-
nisms of action. Moreover, the presence of other compounds such
s hyaluronidases, peptidases and biologically active peptides in
sV are poorly explored [6].
Animal venoms are a rich source of bioactive peptides due the
arge number and diversity of venomous species, and it is esti-
ated that more than 40 million toxins may exist but only 0.01%
ere identiﬁed [15]. Furthermore, it is known that small peptides
re poorly explored because of difﬁculties in their isolation and
haracterization, and also because, frequently, small peptides are
epresented in very low concentrations in the venom of arthro-
ods [14]. Fortunately, the identiﬁcation of molecules using mass
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spectrometry analysis is helping to characterize these neglected
molecules and change the current scenario [14,15].
Through natural selection, scorpion venoms molecules were
conserved to act upon certain physiological mechanisms which are
shared by a great variety of organisms, including human beings.
Therefore, it is probable that compounds like scorpion venom pep-
tides can be prototypes for the development of new drugs. For
example, the chlorotoxin (CTX) from the scorpion Leiurus quinques-
triatus was ﬁrst described as a chloride toxin [8], but nowadays it
has been shown to be effective against the human glioma brain
tumor via inhibition of the MMP-2, an important metallopeptidase
over-expressed by tumor cells [22]. This fact suggests that novel-
ties are still to be discovered, including new functions for already
known molecules.
Thimet oligopeptidase (EP24.15) belongs to the M3 family
metallopeptidase [13] and was ﬁrst described as a neuropeptide-
degrading enzyme present in the soluble fraction of brain
homogenates [12]. The EP24.15 does not have a clear primary
speciﬁcity to cleave substrates, with the ability to accommodate
different amino acid residues at subsites S4 to S3′ [11]. In fact,
EP24.15 shows substrate size restriction to peptides containing
from 5 to 17 amino acids because of its catalytic center, located
in a deep channel [17]. These features of EP24.15 were decisive
Open access under the Elsevier OA license.in successfully describing two new peptides: the human hemo-
pressin [19] and a potent inhibitor of ACE in the venom of Bothrops
jararacussu [20]. Considering theproperty of EP24.15 to select small
molecules and its presence in the nervous system, where the TsV
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ainly acts, the objective of this study was to ﬁnd in TsV new
ioactive peptides selected by interaction with EP24.15 activity in
itro.
. Material and methods
.1. Peptide Pool preparation and initial fractionation
The lyophilized TsV, provided by Butantan Institute, São Paulo,
razil, was suspended in sodium acetate pH 4.0 and immedi-
tely fractionated at 4 ◦C using a 10kDa molecular weight cut off
embrane (Millipore), in order to prevent proteolytic cleavage of
eptides by the crude venom. The ﬁltrated solution (Peptide Pool)
as subjected to reverse phase HPLC (Prominence, Shimadzu),
sing a Shim-pack VP-ODS C-18 column (4.6×150mm); 0.1% TFA
n water (solvent A), and acetonitrile plus solvent A (9:1) as solvent
. The chromatography was performed at a ﬂow rate of 1mL/min
nd detected by ultraviolet absorption (214nm). The peaks were
ollected manually, dried and subjected to enzymatic assays.
.2. EP24.15 enzymatic activity screening
The recombinant EP24.15 was obtained as described [18]. The
eptidase assay was conducted in a 50mM phosphate and 20mM
aCl 7.4 pH buffer containing -mercaptoethanol (1mM) and the
ubstrate QFS (10M), in a ﬁnal volume of 100L. The reactions
ccurred at 37 ◦C and were initiated by the addition of EP24.15
7.5ng), being monitored (EM 420nm and EX 320nm) in a spec-
roﬂuorophotometer (Victor 3TM Perkin–Elmer), as described [20].
he results were obtained in triplicate.
.3. Peptide isolation and mass spectrometry analysis
The single peptide fraction containing inhibitory peptides was
uriﬁed sequentially in the RP-HPLC system described above,
ut with a slower gradient (1.25% B/min), until reaching the
ure peptide, and then subjected to mass spectrometric anal-
ses. The peptide was analyzed by LC–MS/MS on a Synapt G1
ass spectrometer (Waters Co.). The peptide was resuspended in
ater and 2–5L injected onto a Symmetry C18 trapping column
180m×20mm, Waters). The sample was desalted for 15min
nd the trapped peptide was then separated by elution with a
ater/acetonitrile 0.1% formic acid gradient through a BEH 130 –
18 column (100m×100mm, Waters), as previously described
3].Datawasacquired indata-dependentmodeand thepeptidedis-
ociated by collisions with argon. The assays conditions included a
ow rate of 600nL/min, nanoﬂow capillary voltage of 3.5 kV, block
emperature of 100 ◦C, and cone voltage of 100V. The MS spec-
rumwas analyzedmanually from the ESI-MS/MSproduct ionmass
pectra as previously described [19].
.4. Peptide synthesis and identiﬁcation of peptide in Peptide Pool
The peptides KEILG and KELLG were synthesized [1] with a
urity grade greater than 95%. With the aim of determining which
eptide sequence was present in the venom, it was performed a
P-HPLC analysis as described above of a peptide mixture contain-
ng 20L of venom Peptide Pool, with 40M of KEILG and 40M
f KELLG. This mixture was compared to the original Peptide Pool
roﬁle.
.5. Determination of the inhibition constant (Ki)The Ki was determined using seven concentrations of QFS and
wo concentrations of KELLG and KEILG peptides, maintaining the
ame EP24.15 concentration. Controls without the peptides werees 40 (2013) 30–33 31
also performed. The assay was carried out as described before. In
order to analyze the mechanism of inhibition for both peptides,
an Eadie–Hofstee plot was constructed and, based on the type of
mechanism, the Ki was calculated as described [21].
3. Results
After verifying the Peptide Pool inhibitory efﬁciency upon the
QFS hydrolysis by EP24.15, the ﬁrst step of puriﬁcation using a
C-18 reverse-phase was performed. Fourteen peptide peaks were
obtained and submitted to peptidase screening, reaching a single
one responsible for the inhibitory effect. This peak was submit-
ted to the same puriﬁcation method described before, but using a
slowergradient, resulting in threenewpeaks, yetonlyone inhibited
EP24.15 activity. For this reason, it was submitted to LC–MS/MS
analyses, revealing the pentapeptideKEXXG (Fig. 1, panel A),where
X could represent isoleucine/leucine. Two peptides were synthe-
sized, KELLG and KEILG, to observe its performance at RP-HPLC and
inhibition analyses. The retention time (%ACN) range on RP-HPLC
between both peptides was around 1min, indicating a differenti-
ation based on hydrophobicity. After this, a Peptide Pool mixture
containing both peptides as well as a control proﬁle of Peptide Pool
without treatment were prepared, as shown in Fig. 1 (panel B). We
observed that KEILG was already present in the control sample,
while KELLG had no match, changing the proﬁle when compared
with the Peptide Pool. Considering this, we concluded that the
KEILG fragment was the sequence present in the venom. After RP-
HPLC differentiation, the mechanisms and inhibition constants for
both peptides upon EP24.15 activity were determined. It is worth
noting that both peptides were not hydrolyzed by EP24.15 even
after a long period of incubation using bradykinin as a positive
control (data not shown). As shown in Fig. 2, different mech-
anisms of inhibition were found: while KELLG is a competitive
inhibitor (Ki =84M), KEILG acts through an uncompetitive mech-
anism (Ki =16M). In addition, assayswith an EP24.15 homologue,
neurolysin (EC 3.4.24.16; EP24.16)weremade, however, unexpect-
edly, this peptidase was not blocked by any of the two peptides
(data not shown).
4. Discussion
Recently, the study of small peptides has gained importance
through the scientiﬁc community and, in this context, our aim
was to study bioactive peptides from TsV. Animal venoms peptides
have a natural stability and a high selectivity, being preserved dur-
ing evolution, which may suggest a functional importance in the
venom. In addition, the pharmacologic potential of thesemolecules
has attracted the attention of pharmaceutical industries to the
development of new drugs, as previously occurred with other
venom molecules [10].
Due to the obtainment methodology used here, we success-
fully puriﬁed a peptide of only ﬁve residues (K1E2X3X4G5, whereas
X= Leu/Ile). However, we faced a challenge due to the mass spec-
trometry technique employed here that could not determine the
correct amino acid at the indicated positions, since Leu and Ile are
indistinguishable because both are characterized by a 113Da mass
in the MS/MS spectrum.
During our data analysis we noticed a similarity between
K1E2X3X4G5 and the propeptide regions of potassium channel tox-
ins (-KTx) described for Tityus species. All known sequences had
a Leucine in the P4 position, showing to be a conserved residue
among species. On the other hand, the residue in the P3 position
was reported as Valine, in the GKGKEVLGKIK fragment [9] and also
as Isoleucine, in the EKGKEILGKI fragment for T. cambridgei [2]. It is
important to note that these resultswere obtained based on Edman
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Fig. 1. (A) Representative peptide sequencing by LC–MS/MS and (B) RT-HPLC proﬁles: (1) 20L of Peptide Pool from T. serrulatus venom with 40M KEILG and 40M
K KELLG
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cELLG; (2) 20L of Peptide Pool without treatment; (3) 20M KEILG; (4) 20M
ater (solvent A), and acetonitrile and solvent A (9:1) as solvent B. The separatio
4.6×150mm) with a gradient of 1.25% B/min, and elution was followed by ultravi
equencing or by mRNA level. Regarding TsV, there is a description,
y homology level, of the peptide GKGKEILGKIKE (-KTx propep-
ide fragment) using mass spectrometric analysis [16].After the peptides identiﬁcation assay in HPLC, we concluded
hat KEILG was present in the venom, which corresponds to the
eported sequence of the -KTx propeptide from TsV [16]. In
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ig. 2. Eadie–Hofstee plot for Thimet oligopeptidase (EP24.15) in the presence of peptides
hile KEILG is an uncompetitive inhibitor. The inhibition constants (Ki) were determined
0M and 40M), and a variation of KELLG and KEILG peptides concentration (25M a
ontrol experiment (without the peptides). The experiments were made in triplicate.. The analytical procedure was carried out using 0.1% triﬂuoroacetic acid (TFA) in
re performed at a ﬂow rate of 1mL/min using a Shim-pack VP-ODS C-18 column
sorption (214nm).
general, the proposed propeptide function is to prevent activity
of the mature molecule, however other physiological functions are
not well characterized. Therewith, we show here that a fraction
of the -KTx propeptide is present on the venom and have an
important activity in vitro. Considering it, we suggest that -KTx
propeptide is a precursor of bioactive molecules not only for-KTx
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KEILG (A) and KELLG (B). The graph indicates that KELLG is a competitive inhibitor,
using four concentrations of the substrate QFS (4M, 6M, 8M, 10M, 20M,
nd 50M), maintaining the same quantity of thimet oligopeptidase (7.5ng) and a
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ut also for the small peptide KEILG. It is important to emphasize
hat KEILG is certainly a new naturally occurring peptide of TsV
nd not a degradation product of -KTx propeptide, since the TsV
as a low peptidase activity [6] and, moreover, we took preven-
ive measures to avoid degradation of the peptides in the venom,
s previously described here in Section 2.1.
The determinations of the inhibition mechanisms of synthetic
eptides upon EP24.15 show different interactions, as well distinct
i values. The interference of KEILG in enzyme–substrate complex
ould be a result of the isoleucine amino acid afﬁnity to the enzyme
fter conformational changes in the oligopeptidase during its bind-
ng with the substrate, which is consistent with the observations
hat simple amino acid substitutions can change the scissile bond
n substrates [5] or get resistance to its hydrolyses [11], speciﬁcally
or EP24.15. The same hypothesis could explain the KELLG inhibi-
ion mechanism, which only binds in the free peptidase, leading us
o believe that the amino acid in position P3 is crucial to determine
he interaction of this sequence with EP24.15. In addition, none of
he two peptides could inhibit EP24.16 (data not show). We found
his result to be very exciting, since they are members of clan MA,
haring substrates and inhibitors and, until now, no natural peptide
escribed had differentiated EP24.15 and EP.24.16 [7,11,19].
. Conclusion
In summary, the discovery of this peptide suggests a different
rocessing mechanism for the -KTx, since KEILG is a portion of its
ropeptideandshows invitroactivity, emphasizing the importance
f the study of arthropods venom small peptides. In addition, we
escribed a newnaturally occurring peptide fromTsV, KEILG, capa-
le of reducingEP24.15 activity in vitro,whichmaybe an important
ool in further biochemical studies since it is capable of differenti-
te the oligopeptidases EP24.15 and EP24.16. The possible KEILG
ctivity in vivo is under investigation in our laboratories.
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